Insulin Export Market Intelligence: India's 188 Suppliers Shipping to 111 Countries — TransData Nexus 2026

Q: Who are the top insulin exporters from India?

The top insulin exporters from India are: 1. WOCKHARDT LIMITED — $35.9M (47.3% market share); 2. M. J. BIOPHARM PRIVATE LIMITED — $17.3M (22.7% market share); 3. M J BIOPHARM PRIVATE LIMITED — $6.4M (8.4% market share); 4. GLAND PHARMA LTD — $5.2M (6.8% market share); 5. ANGEL BIOGENICS PRIVATE LIMITED — $1.7M (2.2% market share). Together they account for 87.4% of India's total insulin export value.

Q: What is the total export value of insulin from India?

The total export value of insulin from India is $76.0M USD, recorded across 2,532 shipment transactions from 188 active exporters to 111 destination countries. The average shipment value is $30.0K.

Q: Which countries import insulin from India?

India exports insulin to 111 countries worldwide. The top importing countries are: THAILAND (28.6% share, $21.7M), MEXICO (19.2% share, $14.6M), ETHIOPIA (6.5% share, $5.0M), PAKISTAN (6.0% share, $4.5M), DOMINICAN REPUBLIC (4.1% share, $3.1M). These five markets account for 64.5% of total export value.

Q: What is the HS code for insulin exports from India?

The primary HS code for insulin exports from India is 30043110. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of insulin exports from India?

The average unit price for insulin exports from India is $15.38 USD per unit, with prices ranging from $0.00 to $3157.05 depending on formulation, packaging, and order volume. The total market is valued at $76.0M across 2,532 shipments.

Q: Which ports handle insulin exports from India?

The primary ports for insulin exports from India are SAHAR AIR (27.8% of shipments), SAHAR AIR CARGO ACC (INBOM4) (25.5% of shipments), Bombay Air (7.0% of shipments), Bombay Air Cargo (4.9% of shipments), NHAVA SHEVA SEA (INNSA1) (4.3% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of insulin?

India is one of the world's leading exporters of insulin due to its large base of 188 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports insulin to 111 countries, demonstrating 57% global market coverage.

Q: What certifications do Indian insulin exporters need?

Indian insulin exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import insulin from India?

There are 384 registered buyers importing insulin from India, spread across 111 countries. The repeat buyer rate is 66.4%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top insulin supplier from India?

WOCKHARDT LIMITED is the leading insulin exporter from India with a market share of 47.3% and total export value of $35.9M across 454 shipments. The top 5 suppliers together control 87.4% of total export value.

Suresh Sormare

Insulin

India Pharmaceutical Trade Intelligence

$76.0M188 Suppliers111 CountriesHS 30043110

ExportsIndia → THAILAND28.6%India → MEXICO19.2%

ImportsDENMARK → India$358.7B BRAZIL → India$149.3B

#1 Supplier: WOCKHARDT LIMITED

Insulin Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Insulin to the World

Between 2022 and 2026, India exported $76.0M worth of insulin across 2,532 verified shipments to 111 countries — covering 57% of world markets in the Diabetes & Endocrine segment. The largest destination is THAILAND (28.6%). WOCKHARDT LIMITED leads with a 47.3% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30043110

Insulin export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Insulin export data snapshot — $76.0M · 188 exporters · 111 countriesTransData Nexus · Indian Customs Data

Top Insulin Exporters from India

188 active exporters · Ranked by export value

View all 188 →

Top Insulin Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	WOCKHARDT LIMITED	$35.9M	454	25	47.3%
2	M. J. BIOPHARM PRIVATE LIMITED

Top Countries Importing Insulin from India

111 destination markets · Ranked by import value

All 111 countries →

Top Countries Importing Insulin from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	THAILAND	$21.7M	28.6%
2	MEXICO	$14.6M	19.2%
3	ETHIOPIA	$5.0M	6.5%
4	PAKISTAN	$4.5M	6.0%
5	DOMINICAN REPUBLIC	$3.1M	4.1%
6	SRI LANKA	$2.5M	3.3%
7	SAUDI ARABIA	$2.3M	3.0%
8	PERU	$2.0M	2.7%
9	BRAZIL	$1.8M	2.3%
10	MAURITIUS	$1.7M	2.2%

THAILAND is India's largest insulin export destination, absorbing 28.6% of total exports worth $21.7M. The top 5 importing countries — THAILAND, MEXICO, ETHIOPIA, PAKISTAN, DOMINICAN REPUBLIC — together account for 64.5% of India's total insulin export value. The remaining 106 destination countries collectively receive the other 35.5%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Insulin to India?

22 origin countries · Total import value: $726.8B

India imports insulin from 22 countries with a combined import value of $726.8B. The largest supplier is DENMARK ($358.7B, 229 shipments), followed by BRAZIL and GERMANY. All values are from Indian Customs (DGFT) import records.

Countries Supplying Insulin to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	DENMARK	$358.7B	229	49.4%
2	BRAZIL	$149.3B	323	20.5%
3	GERMANY	$87.0B	489	12.0%
4	FRANCE	$61.4B	147	8.4%
5	ITALY	$38.7B	156	5.3%
6	CHINA	$31.1B	83	4.3%
7	UNITED STATES	$444.3M	256	0.1%
8	SWITZERLAND	$15.6M	41	0.0%
9	PORTUGAL	$12.7M	1	0.0%
10	MALAYSIA	$3.9M	101	0.0%

Showing top 10 of 22 origin countries

DENMARK is the largest supplier of insulin to India, accounting for 49.4% of total import value. The top 5 origin countries — DENMARK, BRAZIL, GERMANY, FRANCE, ITALY — together supply 95.7% of India's insulin imports. Click any country to see detailed supplier and buyer data for that import corridor.

Insulin — Export Intelligence Video

Visual overview of India's insulin import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's insulin pharmaceutical import and export market — $76.0M in total trade, 188 verified manufacturers, and 111 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Insulin

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, the U.S. Food and Drug Administration (FDA) has approved numerous Abbreviated New Drug Applications (ANDAs) for insulin products, facilitating the entry of generic versions into the market. The FDA's Orange Book provides a comprehensive list of these approved applications, reflecting the agency's commitment to increasing competition and accessibility in the insulin market.

Regarding import alerts, the FDA issues these to prevent the entry of products that appear to violate U.S. laws and regulations. Import alerts can lead to detention without physical examination (DWPE) of products from specific manufacturers or countries. As of March 2026, there are no active import alerts specifically targeting insulin products from India. However, exporters must remain vigilant, as the FDA regularly updates its import alert list. For instance, on March 9, 2026, the FDA issued Import Alert 66-80, concerning the detention of certain pharmaceutical products due to compliance issues.

The regulatory pathway for insulin products in the U.S. involves demonstrating bioequivalence to a reference product through the ANDA process. Given the presence of 188 active Indian exporters and a repeat buyer rate of 66.4%, maintaining stringent compliance with FDA regulations is imperative to ensure uninterrupted market access.

2EU & UK Regulatory Framework

In the European Union (EU), insulin products require marketing authorization from the European Medicines Agency (EMA). The EMA assesses applications to ensure that medicines meet EU standards for safety, efficacy, and quality. For example, on February 26, 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of marketing authorization for Bysumlog, a biosimilar insulin lispro intended for the treatment of diabetes mellitus. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval of medicinal products. Post-Brexit, the UK has established its own regulatory framework, though it remains aligned with EU standards in many aspects. Compliance with Good Manufacturing Practice (GMP) requirements is mandatory in both jurisdictions, ensuring that insulin products are consistently produced and controlled according to quality standards.

3WHO Essential Medicines & Global Standards

Insulin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in managing diabetes. The WHO Prequalification Programme evaluates medicines to ensure they meet global standards for quality, safety, and efficacy, facilitating their procurement by international agencies.

Insulin products must comply with pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards specify the quality requirements for insulin, including its identity, purity, and potency, ensuring consistency across different markets.

4India Regulatory Classification

In India, insulin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines, including insulin. The NPPA periodically reviews and sets ceiling prices to ensure affordability; the latest revision occurred in January 2026.

For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products. Exporters must comply with these requirements to facilitate the smooth export of insulin products from India.

5Patent & Exclusivity Status

The patent landscape for insulin is complex, with various formulations and delivery methods protected by patents. However, many original patents have expired, leading to increased generic competition. This competitive environment is reflected in the presence of 188 active Indian exporters supplying insulin to 111 destination countries, indicating a robust market for generic insulin products.

6Recent Industry Developments

In February 2026, the EMA's CHMP adopted positive opinions for two biosimilar insulin products: Bysumlog (insulin lispro) and Dazparda (insulin aspart), both intended for the treatment of diabetes mellitus. (ema.europa.eu)

In January 2026, the NPPA revised the ceiling prices for insulin products under the DPCO, aiming to enhance affordability for patients in India.

In March 2026, the FDA issued Import Alert 66-80, concerning the detention without physical examination of certain pharmaceutical products due to compliance issues.

In April 2023, the European Commission withdrew the marketing authorization for Inpremzia (insulin human (rDNA)) at the request of the marketing authorization holder, Baxter Holding B.V., which decided not to market the product in the EU for commercial reasons. (ema.europa.eu)

In February 2025, the FDA issued a safety communication alerting patients to regularly check diabetes-related smartphone device alert settings, especially following phone hardware or software changes, to prevent missed alerts that could lead to serious harm.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Insulin

Retail & reference prices across 8 markets vs. India FOB export price of $15.38/unit

Global Price Benchmark for Insulin across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$131.20	USD	According to data compiled by the World Health Organization (WHO), the average retail price for a 10 mL vial of human insulin in the United States is $131.20. (cdn.who.int)
United Kingdom	$18.82	GBP	The British National Formulary (BNF) lists the average price of a 10 mL vial of human insulin at $18.82. (cdn.who.int)
Australia	$19.00	AUD	The Pharmaceutical Benefits Scheme (PBS) in Australia reports an average price of $19.00 for a 10 mL vial of human insulin. (cdn.who.int)
Brazil

Supply Chain Risk Assessment — Insulin

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's insulin production heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency exposes the supply chain to significant risks, as evidenced by past disruptions. For instance, in 2025, China's implementation of the "Dual Circulation" policy prioritized domestic supply, leading to a 40% reduction in insulin intermediate exports. This policy shift caused global shortages and highlighted the vulnerabilities associated with overreliance on a single source for critical raw materials.

To mitigate such risks, the Indian government has initiated measures to bolster domestic API and KSM production. In November 2025, the Department of Pharmaceuticals launched the sixth application round under the Production Linked Incentive (PLI) scheme for bulk drug manufacturing. This initiative aims to reduce import dependence by encouraging local production of essential pharmaceutical ingredients. As of August 2025, 32 pharmaceutical firms have been selected for greenfield projects, with 48 projects approved across 33 APIs, DIs, and KSMs.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates a high supplier concentration in India's insulin export market. The top five exporters account for 87.4% of total exports, with Wockhardt Limited alone contributing 47.3% ($35.9 million). Such concentration poses a significant single-source risk, as any disruption within these key suppliers could severely impact the global insulin supply chain.

Access Complete Insulin Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,532 transactions across 111 markets.

Request Demo View Pricing

Frequently Asked Questions — Insulin Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top insulin exporters from India?

The leading insulin exporters from India are WOCKHARDT LIMITED, M. J. BIOPHARM PRIVATE LIMITED, M J BIOPHARM PRIVATE LIMITED, and 12 others. WOCKHARDT LIMITED leads with 47.3% market share ($35.9M). The top 5 suppliers together control 87.4% of total export value.

What is the total export value of insulin from India?

The total export value of insulin from India is $76.0M, recorded across 2,532 shipments from 188 active exporters to 111 countries. The average shipment value is $30.0K.

Which countries import insulin from India?

India exports insulin to 111 countries. The top importing countries are THAILAND (28.6%), MEXICO (19.2%), ETHIOPIA (6.5%), PAKISTAN (6.0%), DOMINICAN REPUBLIC (4.1%), which together account for 64.5% of total export value.

What is the HS code for insulin exports from India?

The primary HS code for insulin exports from India is 30043110. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Insulin

Insulin

Top Insulin Exporters from India

Top Countries Importing Insulin from India

Who Supplies Insulin to India?

Quick Facts

Related Diabetes & Endocrine

Related Analysis

Need Details?

Insulin — Export Intelligence Video

Regulatory Landscape — Insulin

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Insulin

Supply Chain Risk Assessment — Insulin

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Insulin Trade Intelligence

Frequently Asked Questions — Insulin Exports from India

Who are the top insulin exporters from India?

What is the total export value of insulin from India?

Which countries import insulin from India?

What is the HS code for insulin exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of insulin exports from India?

Which ports handle insulin exports from India?

Why is India a leading exporter of insulin?

What certifications do Indian insulin exporters need?

How many buyers import insulin from India?

What is the market share of the top insulin exporter from India?

Analysis Methodology